Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.51 HKD | +4.02% | +11.26% | -1.70% |
Mar. 29 | 3D Medicines' 2023 Loss Almost Halves as Revenue Jumps 12% | MT |
Mar. 28 | 3D Medicines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2021 | 60.26 470.15 | Sales 2022 | 567.39 4.43K | Capitalization | 8.38B 65.4B |
---|---|---|---|---|---|
Net income 2021 | -1.43B -11.19B | Net income 2022 | -1.02B -7.99B | EV / Sales 2021 * | - |
Net Debt 2021 | 2.37B 18.47B | Net cash position 2022 | 766M 5.98B | EV / Sales 2022 | 13,423,339 x |
P/E ratio 2021 * |
-
| P/E ratio 2022 |
-1.67
x | Employees | 198 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 0% |
1 day | +4.02% | ||
1 week | +11.26% | ||
Current month | +14.83% | ||
1 month | +38.31% | ||
3 months | +23.11% | ||
6 months | -11.65% | ||
Current year | -1.70% |
Managers | Title | Age | Since |
---|---|---|---|
Zhao Long Gong
CEO | Chief Executive Officer | 60 | 13-12-31 |
Jing Zhang
DFI | Director of Finance/CFO | 50 | 20-08-27 |
Zhi Qiang Xue
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Tat Pang Lin
BRD | Director/Board Member | 67 | 22-11-30 |
Xin Guang Liu
BRD | Director/Board Member | 63 | 21-06-24 |
Zhao Long Gong
CEO | Chief Executive Officer | 60 | 13-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 7.51 | +4.02% | 7,334,000 |
24-05-16 | 7.22 | +2.27% | 2,839,000 |
24-05-14 | 7.06 | +8.28% | 4,557,000 |
24-05-13 | 6.52 | -3.41% | 881,500 |
24-05-10 | 6.75 | 0.00% | 1,258,500 |
Delayed Quote Hong Kong S.E., May 17, 2024 at 04:08 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-1.70% | 218M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.84B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- 1244 Stock